Literature DB >> 17389550

American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.

Joseph S Bertino1, Howard E Greenberg, Michael D Reed.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17389550     DOI： 10.1177/0091270006299092

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  14 in total

1.  Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin.

Authors:  David W Boulton; Sreeneeranj Kasichayanula; Chi Fung Anther Keung; Mark E Arnold; Lisa J Christopher; Xiaohui Sophia Xu; Frank Lacreta
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 2.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 3.  A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug.

Authors:  Ashish A Gawai; Faisal Shaikh; Mangesh Gadekar; Nitin Deokar; Shivanand Kolhe; K R Biyani
Journal:  Turk J Pharm Sci       Date:  2017-04-15

Review 4.  Microdosing and drug development: past, present and future.

Authors:  Graham Lappin; Robert Noveck; Tal Burt
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-04-04       Impact factor: 4.481

5.  Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report.

Authors:  Eben L Rosenthal; Jason M Warram; Esther de Boer; James P Basilion; Merrill A Biel; Matthew Bogyo; Michael Bouvet; Brian E Brigman; Yolonda L Colson; Steven R DeMeester; Geoffrey C Gurtner; Takeaki Ishizawa; Paula M Jacobs; Stijn Keereweer; Joseph C Liao; Quyen T Nguyen; James M Olson; Keith D Paulsen; Dwaine Rieves; Baran D Sumer; Michael F Tweedle; Alexander L Vahrmeijer; Jamey P Weichert; Brian C Wilson; Michael R Zenn; Kurt R Zinn; Gooitzen M van Dam
Journal:  J Nucl Med       Date:  2015-10-08       Impact factor: 10.057

6.  A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.

Authors:  Claudia C Wagner; Marie Simpson; Markus Zeitlinger; Martin Bauer; Rudolf Karch; Aiman Abrahim; Thomas Feurstein; Matthias Schütz; Kurt Kletter; Markus Müller; Graham Lappin; Oliver Langer
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

Review 7.  Approaches using molecular imaging technology -- use of PET in clinical microdose studies.

Authors:  Claudia C Wagner; Oliver Langer
Journal:  Adv Drug Deliv Rev       Date:  2010-09-29       Impact factor: 15.470

8.  Phase 0 - Microdosing strategy in clinical trials.

Authors:  P Usha Rani; M U R Naidu
Journal:  Indian J Pharmacol       Date:  2008-11       Impact factor: 1.200

9.  Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.

Authors:  Tal Burt; Douglas C Rouse; Kihak Lee; Huali Wu; Anita T Layton; Thomas C Hawk; Douglas H Weitzel; Bennett B Chin; Michael Cohen-Wolkowiez; Shein-Chung Chow; Robert J Noveck
Journal:  J Nucl Med       Date:  2015-08-27       Impact factor: 11.082

Review 10.  Imaging and cancer: a review.

Authors:  Leonard Fass
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 7.449
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.